Open AccessEvaluation of the Safety and Immunogenicity of M-M-RII (Combination Measles-mumps-rubella Vaccine)
Author(s) -
Mawuli Nyaku,
Elizabeth Richardson,
Federico MartinónTorres,
Barbara J. Kuter
Publication year - 2021
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000003273
Subject(s) - medicine , rubella , mmr vaccine , adverse effect , measles , reactogenicity , immunogenicity , vaccination , clinical trial , measles mumps rubella vaccine , rubella vaccine , mumps virus , pediatrics , virology , immunology , virus , antibody
The safety and immunogenicity of M-M-RII (measles, mumps and rubella virus vaccine live, Merck & Co., Inc., West Point, PA)-the only combined measles, mumps and rubella vaccine licensed for use in the United States-were previously reported in pre- and postlicensure clinical trials conducted from 1988 to 2009. M-M-RII continues to be evaluated as a comparator in clinical trials of other vaccines. Here, we review safety and efficacy data from more recent clinical trials of M-M-RII.